Agenus (AGEN) Announces Positive Efficacy Data from Glaxo (GSK) Second Shingles Vaccine Phase 3
Agenus (NASDAQ: AGEN) announced that GlaxoSmithKline’s plc (NYSE: GSK) second pivotal Phase III efficacy study of its shingles vaccine candidate ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)